Photo of Reed E. Drews,  MD

Reed E. Drews, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2131
Fax: (617) 667-3915


rdrews@bidmc.harvard.edu

Reed E. Drews, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Director, Hem/Onc. Training Prog and Assistant Director of Education, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

As a member of the BIDMC Cutaneous Oncology Program, Dr. Drews sees patients with non-melanoma skin cancers, including lymphomas and squamous cell, basal cell, and Merkel cell cancers of the skin. He has developed a chief focus in the diagnosis and management of cutaneous lymphoproliferative disorders, including conditions such as lymphomatoid papulosis, mycosis fungoides, Sezary syndrome, primary cutaneous CD30-positive large cell lymphomas and B-cell lymphomas. Since cutaneous lymphoproliferative disorders often pose particular diagnostic challenges, Dr. Drews works as part of a multidisciplinary team of physicians, including hematopathologists and dermatologists, to interpret pathologic findings on patients' biopsies in relation to patients' clinical symptoms and signs. Such clinicopathologic correlation is often an essential determinant for arriving at correct diagnoses. State of the art techniques are also employed to establish correct diagnoses at the earliest possible time, to prevent disease progression, and to recommend appropriate therapies. Research is also on-going to understand better the biology of this group of disorders and identify improved therapies.

Publications

Powered by Harvard Catalyst
  • Tong LX, Weinstock MJ, Drews R, Sheikine Y, Kim CC. Widely Metastatic Squamous Cell Carcinoma Originating from Malignant Transformation of Hypertrophic Lichen Planus in a 24-Year-Old Woman: Case Report and Review of the Literature. Pediatr Dermatol 2015. PubMed
  • Warner JL, Anick P, Drews RE. Physician inter-annotator agreement in the Quality Oncology Practice Initiative manual abstraction task. J Oncol Pract 2013; 9:e96-102. PubMed
  • Drews RE. Emerging treatment options for advanced-stage mycosis fungoides. J Clin Oncol 2012; 30:4064-70. PubMed
  • Drews RE, Shulman LN. Update in hematology and oncology. Ann Intern Med 2010; 152:655-62. PubMed
  • Roetzheim RG, Chirikos TN, Wells KJ, McCarthy EP, Ngo LH, Li D, Drews RE, Iezzoni LI. Managed care and cancer outcomes for Medicare beneficiaries with disabilities. Am J Manag Care 2008; 14:287-96. PubMed
  • Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer. Arch Phys Med Rehabil 2008; 89:595-601. PubMed
  • McCarthy EP, Ngo LH, Chirikos TN, Roetzheim RG, Li D, Drews RE, Iezzoni LI. Cancer stage at diagnosis and survival among persons with Social Security Disability Insurance on Medicare. Health Serv Res 2007; 42:611-28. PubMed
  • Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol 2004; 51:660-2. PubMed
  • Kadin ME, Drews R, Samel A, Gilchrist A, Kocher O. Hodgkin's lymphoma of T-cell type: clonal association with a CD30+ cutaneous lymphoma. Hum Pathol 2001; 32:1269-72. PubMed
  • Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, Kadin ME. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol 2000; 115:1034-40. PubMed
  • Adra CN, Donato JL, Badovinac R, Syed F, Kheraj R, Cai H, Moran C, Kolker MT, Turner H, Weremowicz S, Shirakawa T, Morton CC, Schnipper LE, Drews R. SMARCAD1, a novel human helicase family-defining member associated with genetic instability: cloning, expression, and mapping to 4q22-q23, a band rich in breakpoints and deletion mutants involved in several human diseases. Genomics 2000; 69:162-73. PubMed
  • Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000; 162:347-51. PubMed
  • Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000; 19:109-17. PubMed
  • McCarthy EP, Phillips RS, Zhong Z, Drews RE, Lynn J. Dying with cancer: patients' function, symptoms, and care preferences as death approaches. J Am Geriatr Soc 2000; 48:S110-21. PubMed
  • Drews RE, Kolker MT, Sachar DS, Moran CP, Schnipper LE. Passage to nonselective media transiently alters growth of mycophenolic acid-resistant mammalian cells expressing the escherichia coli xanthine-guanine phosphoribosyltransferase gene: implications for sequential selection strategies. Anal Biochem 1996; 235:215-26. PubMed
  • Manning WJ, Goldberger AL, Drews RE, Goldstein BJ, Matheson JK, Rabinowe SL, Trentham DE, Landsberg L. POEMS syndrome with myocardial infarction: observations concerning pathogenesis and review of the literature. Semin Arthritis Rheum 1992; 22:151-61. PubMed
  • Drews RE, Chan VT, Schnipper LE. Oncogenes result in genomic alterations that activate a transcriptionally silent, dominantly selectable reporter gene (neo). Mol Cell Biol 1992; 12:198-206. PubMed
  • Iezzoni LI, Henderson MG, Bergman A, Drews RE. Purpose of admission and resource use during cancer hospitalizations. Health Care Financ Rev 1991; 13:29-40. PubMed
  • Freedman SD, Drews RE, Glotzer DJ, Kim DS, Gardner H, Galli SJ. Recurrent gastrointestinal bleeding associated with myelofibrosis and diffuse intestinal telangiectasias. Gastroenterology 1991; 101:1432-9. PubMed
Hide